Long-Term Givinostat Data Reinforce Safety Profile in Duchenne Muscular Dystrophy



(MedPage Today) — SAN FRANCISCO — Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggested.
Most treatment-emergent adverse events (TEAEs) were mild to…



Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118270

Author :

Publish date : 2025-11-01 22:00:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version